We have located links that may give you full text access.
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Selegiline in the treatment of behavioural disturbance in Alzheimer's disease.
OBJECTIVE: The purpose of this study was to examine the behavioural and cognitive effects of selegiline in a group of moderately behaviourally disturbed AD patients.
DESIGN: This was a 14-week randomized double-blind placebo-controlled study of selegiline (10 mg) and placebo.
SETTING: An outpatient clinic in an urban-based tertiary referral centre in the USA.
PATIENTS: Twenty-five outpatients meeting NINCDS criteria for probable Alzheimer's disease with associated behavioural disturbance.
MEASURES: The Brief Psychiatric Rating Scale (BPRS), the Dementia Mood Assessment Scale (DMAS) and the Alzheimer Disease Assessment Scale (Cognitive) (ADAS-COG).
RESULTS: In the primary analysis, improvement on the BPRS and DMAS scores with selegeline treatment did not. reach statistical significance. A secondary analysis using a parallel design showed a significant benefit of drug treatment on BPRS scores with a trend towards improvement on the DMAS. Among the 10 subjects who could be tested, there was a significant improvement in cognitive function on the ADAS-COG with selegiline compared to placebo.
CONCLUSIONS: Short-term selegiline treatment produced an improvement in behaviour and had a significant effect on cognition in a subset of testable patients.
DESIGN: This was a 14-week randomized double-blind placebo-controlled study of selegiline (10 mg) and placebo.
SETTING: An outpatient clinic in an urban-based tertiary referral centre in the USA.
PATIENTS: Twenty-five outpatients meeting NINCDS criteria for probable Alzheimer's disease with associated behavioural disturbance.
MEASURES: The Brief Psychiatric Rating Scale (BPRS), the Dementia Mood Assessment Scale (DMAS) and the Alzheimer Disease Assessment Scale (Cognitive) (ADAS-COG).
RESULTS: In the primary analysis, improvement on the BPRS and DMAS scores with selegeline treatment did not. reach statistical significance. A secondary analysis using a parallel design showed a significant benefit of drug treatment on BPRS scores with a trend towards improvement on the DMAS. Among the 10 subjects who could be tested, there was a significant improvement in cognitive function on the ADAS-COG with selegiline compared to placebo.
CONCLUSIONS: Short-term selegiline treatment produced an improvement in behaviour and had a significant effect on cognition in a subset of testable patients.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app